Company Insights

CLGN customer relationships

Explore interactive graphBrowse insights index
CLGN customer relationship map

CollPlant (CLGN): Partner-led commercialization of rhCollagen — milestone economics and concentrated counterparty exposure

CollPlant monetizes proprietary plant-derived recombinant human collagen (rhCollagen) and related bioinks through a mix of strategic development and commercialization partnerships, licensing deals for organ and tissue bioprinting, milestone and royalty receipts, and targeted product sales (eg. Vergenix for wound care). Revenue is currently driven by milestone payments from large pharma partners and early product distributions rather than broad commercial sales, positioning the company as a high-upside, partner-dependent bioproduct supplier for aesthetic and regenerative medicine markets. For further diligence on counterparty exposures and relationship histories, visit https://nullexposure.com/.

How CollPlant runs the business and why partners matter

CollPlant operates as a specialized materials and platform provider to larger healthcare and device firms. The company’s economic model is partnership-first: it licenses rhCollagen/BioInk technologies to strategic collaborators, supplies material during partners’ development programs, and collects milestone payments and potential downstream royalties. CollPlant also sells clinical and preclinical products (eg. Vergenix) and expands distribution into specific regions.

  • Contracting posture: CollPlant follows a collaboration and licensing approach rather than vertical commercialization alone; partners assume clinical and regulatory burden for many end-market products.
  • Concentration: Revenue is concentrated with a handful of large partners — milestone receipts from one or two counterparties are a material component of recent revenue.
  • Criticality: CollPlant’s rhCollagen is a specialized input for 3D bioprinting and certain soft‑tissue/implant applications, creating high technical stickiness for partners once integrated.
  • Maturity: The business is mid‑development: preclinical-to-clinical programs coexist with early product commercialization and milestone-driven cash flow, so earnings volatility is structural.

These company-level signals suggest a capital-efficient upstream business that trades off revenue predictability for upside via partner-led development. Learn more about tracking counterparty risk at https://nullexposure.com/.

Customer relationships — one-by-one, plain-English summaries

Below are each of the relationships referenced in the source set, with a concise description and a source citation for verification.

AbbVie

CollPlant’s collaboration with AbbVie focuses on developing a dermal and soft‑tissue filler where CollPlant supplies technology and AbbVie handles clinical development and commercialization, with AbbVie paying development milestones; CollPlant reported milestone receipts in multiple periods, including a $10 million payment tied to a development milestone (FY2024) and further milestone payments in FY2025–FY2026 coverage. Source: CollPlant press releases and financial updates summarized in PR Newswire and company filings (FY2024–FY2026).

Allergan

Allergan is repeatedly referenced as the original counterparty for CollPlant’s dermal filler program; in public materials CollPlant explains the 2021 agreement with Allergan (now part of AbbVie) for development and global commercialization of dermal and soft‑tissue fillers. Source: multiple CollPlant press releases and investor updates cited via PR Newswire and StockTitan (FY2025–FY2026 disclosures).

AbbVie Inc.

Corporate communications and earnings materials reference AbbVie Inc. as the contractual partner that triggered material milestone payments to CollPlant (notably the $10 million milestone in 2023 and subsequent payments), confirming that AbbVie — whether referred to as AbbVie or AbbVie Inc. — is the primary pharma counterparty for the filler program. Source: Biospace coverage of CollPlant Q3 financials and PR Newswire investor letters (FY2023–FY2024).

Allergan (an AbbVie company)

Public statements often use the phrase “Allergan (an AbbVie company)” to reflect the acquisition and to describe the historic Allergan agreement that now sits under AbbVie’s umbrella; CollPlant continues to reference that agreement in regulatory and patent announcements. Source: CollPlant press releases and SEC filings distributed on PR Newswire and StockTitan (FY2024–FY2026).

United Therapeutics Corporation

CollPlant granted United Therapeutics a licensing relationship for use of CollPlant’s BioInk in organ manufacturing efforts, and United Therapeutics exercised an option to expand collaboration into 3D‑bioprinted kidneys, with CollPlant committing to manufacture and supply BioInk and provide technical support during development. Source: PR Newswire announcement of the option exercise (FY2020).

United Therapeutics

Coverage also lists United Therapeutics (name variant) for a related licensing/distribution arrangement where CollPlant’s BioInks are used in lung and organ bioprinting programs; CollPlant has described multi‑year supply and support commitments tied to United Therapeutics’ development needs. Source: CollPlant press release distributed on PR Newswire and related StockTitan summaries (FY2020).

Lung Biotechnology PBC

Lung Biotechnology PBC — United Therapeutics’ organ‑manufacturing subsidiary — received an exclusive license to CollPlant’s rhCollagen‑based BioInk for bioprinting human kidneys, evidencing CollPlant’s role as a licensed supplier to organ‑scale manufacturing programs. Source: PR Newswire release detailing the option exercise and exclusive license (FY2020).

Mayo Clinic

Academic collaboration: Mayo Clinic researchers developed a fully humanized 3D bioprinted human skin model using CollPlant’s rhCollagen bioink, demonstrating scientific validation and translational interest from a top clinical research institution. Source: Finviz report summarizing the Mayo Clinic announcement (FY2025).

3D Systems

CollPlant entered a partnership with 3D Systems to explore integrated bioprinting solutions combining 3D Systems’ printing hardware with CollPlant’s biomaterials, signaling a channel strategy to align material supply with leading additive manufacturing platforms. Source: TCT Magazine coverage of the 3D Systems–CollPlant collaboration (FY2020).

Investment implications and risk checklist

  • Revenue sensitivity to milestones: Recent revenue includes discrete milestone receipts (eg. large AbbVie payments), so forward revenue visibility is binary around partner achievements.
  • Concentration risk: A small set of large partners materially influences cash flow, increasing counterparty concentration risk.
  • Strategic optionality: Partnerships with device OEMs (3D Systems) and academic validation (Mayo Clinic) create optional pathways to diversify revenue beyond cosmetic fillers.
  • Execution and regulatory risk: Transitioning from partner‑led R&D to recurring product sales requires regulatory approvals and manufacturing scale; the company’s current model deliberately offloads much of that work to partners.

If you need a tailored counterparty risk map or a signal-driven update on CollPlant’s partner payments, start a deep dive at https://nullexposure.com/.

Bottom line for investors and operators

CollPlant is a partnership-centric supplier of differentiated biomaterials where upside is driven by a few high-value collaborations and milestone events. That structure offers asymmetric upside if partners commercialize successful aesthetics or regenerative products, but it also concentrates downside if partner programs delay or fail. For investors evaluating CLGN, the decision hinges on confidence in AbbVie/Allergan’s development timeline and the company’s ability to convert scientific validation (eg. Mayo Clinic) and platform partnerships (3D Systems, United Therapeutics) into recurring product revenue. For more on tracking counterparty payments and mapping strategic exposures, visit https://nullexposure.com/.